Publications
Antibody Therapeutics
Use of bifunctional hybrid beta-lactamases for epitope mapping and immunoassay development.
(Chevigne A, Yilmaz N, Gaspard G, Giannotta F, Francois JM, Frère JM, Galleni M, Filée P. J Immunol Methods. 2007; Vol. 30; pp 81-93.)
Protein Therapeutics
The Bacillus licheniformis BlaP beta-lactamase as a model protein scaffold to study the insertion of protein fragments.
(Vandevenne M, Filee P, Scarafone N, Cloes B, Gaspard G, Yilmaz N, Dumoulin M, François JM, Frère JM, Galleni M.Protein Sci. 2007; Vol.16; n°10; pp 2260-71.)
Rapid and easy development of versatile tools to study protein/ligand interactions.
(Vandevenne M, Gaspard G, Yilmaz N, Giannotta F, Frère JM, Galleni M, Filée P.
Protein Eng Des Sel. 2008; Vol. 21; n°7; pp 443-51.)
Vaccine Development
DNA vaccination for the priming of neutralizing antibodies against non-immunogenic STa enterotoxin from enterotoxigenic Escherichia coli.
(Ruth N, Mainil J, Roupie V, Frère JM, Galleni M, Huygen K. Vaccine. 2005; Vol. 20; pp 3618-27.)
Enabling Technology
Creating hybrid proteins by insertion of exogenous peptides into permissive sites of a class A beta-lactamase.
(Ruth N, Quinting B, Mainil J, Hallet B, Frère JM, Huygen K, Galleni M.)
Design, synthesis, and biological evaluation of a cephalosporin-monohydroguaiaretic acid prodrug activated by a monoclonal antibody-beta-lactamase conjugate.
(Hakimelahi GH et al. Bioorg Med Chem. 2002; Vol10; pp 2927-32.)
Antibody-enzyme conjugates for cancer therapy.
(Melton RG et Sherwood RF. J Natl Cancer Inst. 1996; Vol. 21; pp 153-65.)
Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug.
(Wang Y, Yuan H, Wright SC, Wang H, Larrick JW. BMC Chemical Biology. 2001; Vol. 1; p 4.)